Clinical Trial

Investigation of Subclinical Markers of Multiple Sclerosis

Study acronym: SUBCLIN-MS

Recruiting

Record status

This record was last updated October 2, 2023 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.

Summary

Transcranial magnetic stimulation (TMS) studies reported consistent and substantial impairments in the central nervous system (CNS) in multiple sclerosis (MS). Studies of peripheral nervous system (PNS) function comprising electromyoneurography (EMNG) reported impairments of the PNS in MS that were less pronounced and inconsistent. Neurophysiological studies are generally small and cross-sectional and with the poor grouping of MS patients according to MS type. The objective of the study is to investigate clinical, neurophysiological, and immunological markers in relapsing-remitting MS patients, and in patients with relapsing-remitting MS treated with immunomodulation. The results of the study may contribute to a better understanding of the pathophysiology of multiple sclerosis and can provide guidance in the diagnosis and treatment of patients with relapsing-remitting MS.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2020-10-20; most recent amendment 2023-09-28.

Status change: Not Yet Recruiting → Recruiting 2020-11-23

Trial Details

NCT Number	NCT04604041
Lead Sponsor	University of Split, School of Medicine Collaborators: University Hospital of Split
Conditions	Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Enrollment	50 participants
Start Date	2020-11-23
Primary Completion	2024-12 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2023-10-02